Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NVS · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer NCT07908667 · Extensive-stage Small Cell Lung Cancer TRB191 | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting was not yet recruiting | 120 | Jul 30, 2030 | Registry ↗ |
| Nov 13, 2026 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofi… Pelabresib, Ruxolitinib | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 460 | May 17, 2028 | Registry ↗ |
| Nov 13, 2026 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. D… NCT07190300 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide | NVS Novartis Pharmaceuticals | Phase 1/2 | Recruiting | 181 | Aug 2, 2032 | Registry ↗ |
| Nov 13, 2026 | A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Me… NCT07047118 · Prostatic Cancer, Castration-Resistant JSB462, AAA617 | NVS Novartis Pharmaceuticals | Phase 2 | Active, not recruiting | 138 | Jul 16, 2027 | Registry ↗ |
| Nov 13, 2026 | An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patie… NCT06991556 · Metastatic Hormone-sensitive Prostate Cancer JSB462, Abiraterone | NVS Novartis Pharmaceuticals | Phase 2 | Active, not recruiting | 168 | Dec 3, 2026 | Registry ↗ |
| Nov 13, 2026 | Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia NCT06858332 · Atherosclerotic Cardiovascular Disease Atorvastatin, Simvastatin | NVS Novartis Pharmaceuticals | — | Recruiting | 2,382 | Sep 30, 2027 | Registry ↗ |
| Nov 13, 2026 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer NCT05827081 · Early Breast Cancer Ribociclib, Letrozole | NVS Novartis Pharmaceuticals | Phase 3 | Active, not recruiting | 1,466 | Sep 7, 2029 | Registry ↗ |
| Nov 13, 2026 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced… NCT05462873 · Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell QEQ278 | NVS Novartis Pharmaceuticals | Phase 1 | Terminated | 30 | Jan 26, 2026 | Registry ↗ |
| Nov 13, 2026 | A Registry of Patients With Moderate to Severe Plaque Psoriasis NCT02786186 · Psoriasis Secikinumab | NVS Novartis Pharmaceuticals | — | Completed | 2,376 | Jan 22, 2026 | Registry ↗ |
| Nov 12, 2026 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fract… NCT07465653 · Heart Failure With Reduced Ejection Fraction HJB647 low dose, HJB647 high dose | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting | 12 | Dec 8, 2026 | Registry ↗ |
| Nov 12, 2026 | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Phila… NCT07387926 · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acut… Asciminib Adult formulation, Asciminib Pediatric formulation | NVS Novartis Pharmaceuticals | Phase 1/2 | Recruiting | 50 | Sep 19, 2033 | Registry ↗ |
| Nov 12, 2026 | An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Ver… NCT06894511 · Metastatic Castration Resistant Prostate Cancer (mCRPC) AAA617, ARPI: Abiraterone | NVS Novartis Pharmaceuticals | Phase 2 | Active, not recruiting | 7 | Nov 17, 2026 | Registry ↗ |
| Nov 12, 2026 | Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppu… NCT06785675 · Hidradenitis Suppurativa Secukinumab | NVS Novartis Pharmaceuticals | — | Completed was active, not recruiting | 63 | Jul 16, 2026 | Registry ↗ |
| Nov 12, 2026 | ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS NCT06733922 · Relapsing Remitting Multiple Sclerosis (RRMS) ETNATM-ProgMS | NVS Novartis Pharmaceuticals | Phase 4 | Recruiting | 224 | Mar 31, 2029 | Registry ↗ |
| Nov 12, 2026 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib NCT06401356 · Hematologic Malignancy, Solid Tumor Pelabresib, Ruxolitinib | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 50 | Dec 31, 2029 | Registry ↗ |
| Nov 12, 2026 | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140 · Atypical Hemolytic Uremic Syndrome Iptcaopan 200 mg | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 65 | Jul 16, 2032 | Registry ↗ |
| Nov 12, 2026 | Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Throm… NCT05653349 · Primary Immune Thrombocytopenia (ITP) Ianalumab, Placebo | NVS Novartis Pharmaceuticals | Phase 3 | Active, not recruiting | 226 | Oct 29, 2026 | Registry ↗ |
| Nov 12, 2026 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/… NCT05268289 · Lupus Nephritis Iptacopan (part 1), Iptacopan (part 2) | NVS Novartis Pharmaceuticals | Phase 2 | Terminated | 81 | Mar 19, 2026 | Registry ↗ |
| Nov 12, 2026 | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multip… NCT05156281 · Relapsing Multiple Sclerosis Remibrutinib, Teriflunomide | NVS Novartis Pharmaceuticals | Phase 3 | Active, not recruiting | 1,007 | Jul 22, 2026 | Registry ↗ |
| Nov 12, 2026 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refra… NCT02962414 · Tuberous Sclerosis Complex everolimus | NVS Novartis Pharmaceuticals | Phase 3 | Active, not recruiting | 206 | Feb 26, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor… NCT07928037 · Metastatic Castration-Resistant Prostate Cancer | NVS Novartis Pharmaceuticals | — | Not yet recruiting | 2,045 | Nov 25, 2026 | Registry ↗ |
| Nov 10, 2026 | A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS NCT07855276 · Hidradenitis Suppurativa LOU064, Placebo | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting | 30 | Nov 29, 2027 | Registry ↗ |
| Nov 10, 2026 | A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abe… NCT07737756 · Spinal Muscular Atrophy | NVS Novartis Pharmaceuticals | — | Not yet recruiting | 6 | Feb 28, 2027 | Registry ↗ |
| Nov 10, 2026 | A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Ad… NCT07681271 · Papulopustular Rosacea LOU064, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 100 | Dec 7, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf… NCT07681258 · Chronic Myeloid Leukemia | NVS Novartis Pharmaceuticals | — | Not yet recruiting | 80 | Sep 1, 2027 | Registry ↗ |
| Nov 10, 2026 | A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Dos… NCT07604324 · Dermatitis, Atopic DCY636, Placebo | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting | 63 | Jan 27, 2028 | Registry ↗ |
| Nov 10, 2026 | A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Establ… NCT07454889 · Hidradenitis Suppurativa | NVS Novartis Pharmaceuticals | — | Not yet recruiting | 34 | Oct 30, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leuke… NCT07454850 · Leukemia, Myeloid, Chronic-Phase | NVS Novartis Pharmaceuticals | — | Not yet recruiting | 400 | Jul 2, 2027 | Registry ↗ |
| Nov 10, 2026 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP NCT07354074 · Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chroni… Asciminib single agent | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 50 | Feb 23, 2033 | Registry ↗ |
| Nov 10, 2026 | Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model i… NCT07249463 · Cryptosporidiosis Cryptosporidium parvum oocysts (ABO809), EDI048 | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 80 | Mar 23, 2027 | Registry ↗ |
| Nov 10, 2026 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Par… NCT07235059 · Chronic Kidney Disease OJR520, Placebo | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting | 112 | Jan 21, 2028 | Registry ↗ |
| Nov 10, 2026 | EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelis… NCT06997588 · PIK3CA-related Overgrowth Spectrum (PROS) Alpelisib | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 140 | Jan 29, 2029 | Registry ↗ |
| Nov 10, 2026 | A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. NCT06632600 · Chagas Disease LXE408, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 130 | Jul 22, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in… NCT06439082 · Sickle Cell Disease Crizanlizumab, Placebo | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 354 | Jul 2, 2029 | Registry ↗ |
| Nov 10, 2026 | A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated… NCT06019637 · Spinal Muscular Atrophies Onasemnogene Abeparvovec | NVS Novartis Pharmaceuticals | — | Recruiting | 50 | Jan 2, 2042 | Registry ↗ |
| Nov 10, 2026 | A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever NCT06006559 · Dengue EYU688, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 108 | Jul 22, 2027 | Registry ↗ |
| Nov 10, 2026 | An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQ… NCT05900141 · Hyperlipoproteinemia (a) Pelacarsen | NVS Novartis Pharmaceuticals | Phase 3 | Terminated was active, not recruiting | 41 | Oct 15, 2026 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide… NCT05776927 · Asthma QVM149, Salmeterol Xinafoate / Fluticasone Propionate | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 188 | Dec 30, 2028 | Registry ↗ |
| Nov 10, 2026 | Kesimpta (Ofatumumab) Pregnancy Registry NCT05634967 · Multiple Sclerosis, Pregnancy Kesimpta | NVS Novartis Pharmaceuticals | — | Recruiting | 725 | Feb 28, 2033 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Vers… NCT05562466 · Asthma QMF149, Budesonide | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 200 | Feb 1, 2028 | Registry ↗ |
| Nov 10, 2026 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malign… NCT05541341 · Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia tisagenlecleucel | NVS Novartis Pharmaceuticals | — | Recruiting | 200 | Nov 23, 2037 | Registry ↗ |
| Nov 10, 2026 | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children… NCT05222529 · Asthma Glycopyrronium bromide 25ug, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 42 | Jul 30, 2027 | Registry ↗ |
| Nov 10, 2026 | Dabrafenib and/or Trametinib Rollover Study NCT03340506 · Melanoma, Non Small Cell Lung Cancer dabrafenib, trametinib | NVS Novartis Pharmaceuticals | Phase 4 | Recruiting | 100 | Dec 28, 2032 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable S… NCT07908680 · Schizophrenia XEP527, Placebo | NVS Novartis Pharmaceuticals | Phase 1 | Recruiting was not yet recruiting | 36 | Mar 6, 2028 | Registry ↗ |
| Nov 9, 2026 | Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Ch… NCT07816328 · Chronic Spontaneous Urticaria Remibrutinib, Omalizumab | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 382 | May 24, 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With S… NCT07811869 · Chronic Pruritus of Unknown Origin Remibrutinib, Placebo | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 180 | Feb 26, 2029 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to… NCT07801495 · Moderate to Severe Psoriatic Arthritis DDY391, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 220 | Dec 13, 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Mo… NCT07775924 · Cutaneous Lichen Planus Placebo, GIA632 | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 259 | Nov 22, 2028 | Registry ↗ |
| Nov 9, 2026 | A 52-week Study of Remibrutinib in IgE-mediated Food Allergy NCT07768371 · IgE-Mediated Food Allergy, Peanut Allergy Remibrutinib, Placebo | NVS Novartis Pharmaceuticals | Phase 3 | Recruiting | 576 | Mar 30, 2029 | Registry ↗ |
| Nov 9, 2026 | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXA… NCT07748624 · VEXAS Syndrome Arumakimig, Placebo | NVS Novartis Pharmaceuticals | Phase 2 | Recruiting | 120 | Dec 26, 2028 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:30 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances